Grifols (NASDAQ:GRFS) Upgraded to "Hold" at Zacks Investment

Zacks Investment Research upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a sell rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]

Related Keywords

Spain , Barcelona , Comunidad Autonoma De Cataluna , , Lindbrook Capital , Advisornet Financial Inc , Grifols Company Profile Get Rating , Berenberg Bank , Zacks Investment Research , Hospital Division , Jpmorgan Chase Co , Advisors Inc , Bioscience Division , Transfusion Centers , Get Rating , Diagnostic Division , Hospital Blood Banks , Wealth Advisors , Net Financial Inc , Company Profile , Bio Supplies , Bioscience Segment , Hospital Segment , Grifols , Nasdaq Grfs , Grfs , Medical , Upgrade ,